Prebiopsy multiparametric MRI and PI-RADS version 2.0 for differentiating histologically benign prostate disease from prostate cancer in biopsies: A retrospective single-center comparison

2021 ◽  
Author(s):  
Mesude Tosun ◽  
Hande Uslu
Keyword(s):  
Prostate Cancer ◽  
Multiparametric Mri ◽  
Single Center ◽  
Prostate Disease ◽  
Version 2.0 ◽  
Benign Prostate

scholarly journals Risk of prostate cancer associated with benign prostate disease: a primary care case–control study

2011 ◽  
Vol 61 (592) ◽  
pp. e684-e691 ◽  
Author(s):  
Brian S Buckley ◽  
Marie Carmela M Lapitan ◽  
Colin R Simpson ◽  
Aziz Sheikh
Keyword(s):  
Prostate Cancer ◽  
Primary Care ◽  
Case Control Study ◽  
Case Control ◽  
Prostate Disease ◽  
Benign Prostate ◽  
Control Study

scholarly journals Novel immunoassay for the measurement of complexed prostate-specific antigen in serum

1998 ◽  
Vol 44 (6) ◽  
pp. 1216-1223 ◽  
Author(s):  
W Jeffrey Allard ◽  
Zeqi Zhou ◽  
Kwok K Yeung
Keyword(s):  
Prostate Cancer ◽  
Monoclonal Antibody ◽  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
Binding Properties ◽  
Prostate Disease ◽  
Free Psa ◽  
Total Psa ◽  
Benign Prostate ◽  
Artificial Mixtures

Abstract Serum prostate-specific antigen (PSA) is an effective diagnostic tool for detection of prostate cancer (CaP) at an early and potentially curable stage, but specificity is low. Studies have shown that the proportion of serum PSA complexed with α-1-antichymotrypsin (ACT) is higher in men with CaP than in men with benign prostate disease. We developed a novel immunoassay for complexed PSA based on the unique binding properties of a monoclonal antibody that fails to bind free PSA in the presence of antibodies specific for free PSA. The assay measured mixtures of free and complexed PSA accurately, and the measured values of free + complexed PSA in artificial mixtures and in patient sera were equivalent to the measured value of total PSA. Both the serum concentration and the proportion of complexed PSA was substantially higher in patients with CaP compared with patients with benign prostate disease. The cPSA assay may have utility in improving specificity in screening for prostate cancer.

Detection of circulating tumor cells in men with localized prostate cancer.

1994 ◽  
Vol 12 (12) ◽  
pp. 2634-2639 ◽  
Author(s):  
M V Seiden ◽  
P W Kantoff ◽  
K Krithivas ◽  
K Propert ◽  
M Bryant ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Peripheral Blood ◽  
Systemic Disease ◽  
Control Group ◽  
Rt Pcr ◽  
Pcr Assay ◽  
Prostate Disease ◽  
Benign Prostate

PURPOSE Using prostate-specific antigen (PSA) mRNA as a marker for prostatic epithelial cells, we have developed a sensitive technique that involves reverse transcription and polymerase chain reaction (RT-PCR) to detect circulating tumor cells in the peripheral blood of men with prostatic carcinoma (CaP). PATIENTS AND METHODS A sensitive RT-PCR assay was used to evaluate the peripheral blood of 135 men with a history of CaP. Fourteen men with benign prostate disease, many of whom had elevated serum PSA levels, were used as a control group. RESULTS All patients with benign prostate disease had a negative result in the RT-PCR assay. Of particular interest was a subgroup of 65 patients with clinically localized CaP evaluated before definitive local therapy. Five of these patients had detectable PSA mRNA by RT-PCR, suggesting circulating tumor cells. Within this group, systemic disease was detected by RT-PCR in some men with PSA levels less than 10 ng/mL and clinical stage B disease. Blood from men with hormone-refractory and progressive CaP demonstrated a higher frequency of PSA mRNA detectable by RT-PCR (10 of 20 patients). In contrast, none of seven patients with newly diagnosed metastatic prostate cancer and only one of seven patients with metastatic, hormone-responsive disease had blood that was positive for PSA mRNA by RT-PCR. CONCLUSION Circulating tumor cells can be detected in the blood of a subset of patients with clinically localized CaP and a larger subset of patients with progressive metastatic disease.

Micro-ultrasound versus multiparametric MRI in the detection of prostate cancer: Results from a prospective single center trial

2019 ◽  
Vol 18 (11) ◽  
pp. e3410
Author(s):  
D. Maffei ◽  
M. Paciotti ◽  
M. Lazzeri ◽  
N. Frego ◽  
V. Fasulo ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Multiparametric Mri ◽  
Single Center

Prostate-specific Antigen (PSA) and Cancer-Associated Serum Antigen (CASA) in Distinguishing Benign and Malignant Prostate Disease

1995 ◽  
Vol 10 (4) ◽  
pp. 221-225 ◽  
Author(s):  
P.L. Devine ◽  
M.D. Walsh ◽  
M. A. McGuckin ◽  
R. J. Quin ◽  
B. G. Hohn ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
Benign Disease ◽  
Poor Correlation ◽  
Predictive Values ◽  
Prostate Disease ◽  
Serum Antigen ◽  
Benign Prostate ◽  
Malignant Prostate

The Prostate-Specific Antigen (PSA) and the Cancer-Associated Serum Antigen (CASA) assay for the MUC1 mucin were compared in the serum of 303 patients with malignant or benign prostatic disease. Using cutpoints of 4, 10, and 20 μg/l, PSA was elevated in 93%, 81%, and 64% of patients with prostate cancer (n = 113), with corresponding specificities of 55%, 84%, and 96% in benign prostate disease (prostatic hyperplasia or prostatitis, n = 190). Using the recommended cutpoint of 4 Units/ml, CASA was elevated in 38% of patients with prostate cancer, with a specificity of 91% in benign disease. PSA and CASA showed a poor correlation in prostate cancer (r = 0.367) and benign disease (r = 0.158), and CASA was elevated in some PSA negative samples. Used together, PSA ≥20 μg/l and CASA ≥4 kU/l gave perfect specificity in benign disease, with a corresponding sensitivity of 29% (positive and negative predictive values of 100% and 70%, respectively). However, this combination gave no improvement over the use of PSA alone, with sensitivity 47% when the cutpoint was raised to give perfect specificity. These data suggest that CASA is of little use as an adjunct to PSA in the differentiation of benign and malignant prostate disease.

Sign in / Sign up

Export Citation Format

Share Document